USE OF THE BASIC FORM OF RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF PATIENTS WITH SPINOCEREBELLAR ATAXIA WITH CAG REPEAT MUTATIONS

摘要

Summary: ;The present invention relates to use of pharmaceutical compositions that have as active ingredient the basic form of recombinant human erythropoietin (rhEPO) and that are administered nasally for the treatment of spinocerebellar ataxia (SCA) with mutations of CAG repeats type, particularly of SCA type 2. Another object of the present invention is a method for stratifying patients into responders and non-responders to treatment with the basic form of rhEPO.